Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110150 | 0.83 | L3MBTL1 (0.49) | ALDH1A1HPGDNPSR1MAPTPOLB | |
| SCHEMBL12946184 | 0.76 | NPC1 (0.37) | NPC1ALDH1A1 | |
| SCHEMBL952164 | 0.75 | NPC1 (0.42) | TSHRNPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12777661 | 0.74 | MAPT (0.40) | TSHRNPC1ALDH1A1NPSR1MAPT | |
| SCHEMBL948904 | 0.74 | NPC1 (0.36) | NPC1NPSR1MAPTKDM4E | |
| SCHEMBL2703610 | 0.73 | TEAD2 (0.36) | TSHRALDH1A1HPGDMAPK1NPSR1 | |
| SCHEMBL18394574 | 0.73 | BAZ2B (0.40) | TSHRNPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL129089 | 0.73 | HSD17B10 (0.36) | TSHRNPC1ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2703787 | 0.72 | LMNA (0.42) | TSHRNPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL267991 | 0.72 | SMN1; SMN2 (0.48) | TSHRNPC1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
| CN-101970424-B | Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity | VERNALIS R&D LTD | 2013-06-12 | — | — | CN | disclosed |
| EP-2294065-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | Vernalis (R&D) Ltd. (GB) | 2011-03-16 | — | — | EP | disclosed |
| CN-101970424-A | Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity | VERNALIS R&D LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | TSHR 1206/4885NPC1 4503/4885ALDH1A1 1004/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | TSHR 2045/4885NPC1 4017/4885ALDH1A1 1710/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | TSHR 2045/4885NPC1 4017/4885ALDH1A1 1710/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | TSHR 2045/4885NPC1 4017/4885ALDH1A1 1710/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | TSHR 1422/4885NPC1 4696/4885ALDH1A1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.